OBJECTIVE: To assess the effectiveness and safety of Kuntai capsule and hormone replacement therapy in treatment of perimenopausal syndrome.METHODS: Articles were retrieved from the databases Cochrane Database of Syst...OBJECTIVE: To assess the effectiveness and safety of Kuntai capsule and hormone replacement therapy in treatment of perimenopausal syndrome.METHODS: Articles were retrieved from the databases Cochrane Database of Systematic Reviews,Pub Med, Chinese National Knowledge Infrastructure, China Science and Technology Journal Database, and Wanfang Database. Only randomized controlled trials were included; 15 trials involving1243 patients were identified from January 2005 to April 2015. A systemic review and Meta-analysis of publications was performed. The review was limit-ed to randomized controlled trials that compared Kuntai capsule and hormone replacement therapy to treat perimenopausal syndrome for at least 3months. The primary outcome assessed was the treatment efficacy at 3 months, including effective rate of Kupperman menopausal scores, Kupperman menopausal scores, and blood estradiol(E2) or blood follicle stimulating hormone(FSH) levels.Other outcomes assessed were safety or adverse events, such as gastrointestinal complaints, breast distending pain, or vaginal bleeding.RESULTS: Kupperman menopausal scores showed no significant difference in effective rate [odds ratio(OR): 1.05, 95% confidence intervals(CI): 0.71 to1.55] and changes in FSH level [mean difference(MD): 2.14, 95% CI:-2.36 to 6.65]. There was a significant statistical difference in Kupperman menopausal scores(MD:-1.14, 95% CI:-2.03 to-0.25)and changes in E2level(MD:-16.41, 95% CI:-18.83to-13.69). There were fewer adverse events in the Kuntai capsule group than in the hormone replacement therapy group(OR: = 0.35, 95% CI: 0.25 to0.48, P < 0.01).CONCLUSION: Compared with hormone replacement therapy, Kuntai capsule can improve perimenopausal symptoms and blood E2 levels, and reduce the incidence of adverse events.展开更多
目的通过对女性围绝经健康人群和情绪障碍人群的临床对比研究,以期探索生活事件、人格特征、应付方式等社会心理因素在女性围绝经期情绪障碍中的作用.方法研究对象为在中山大学附属第三医院心理科住院的抑郁为主伴或不伴焦虑的围绝经期...目的通过对女性围绝经健康人群和情绪障碍人群的临床对比研究,以期探索生活事件、人格特征、应付方式等社会心理因素在女性围绝经期情绪障碍中的作用.方法研究对象为在中山大学附属第三医院心理科住院的抑郁为主伴或不伴焦虑的围绝经期女性患者57例,以及来自到广州市海珠区妇幼保健医院参加体检的、经焦虑自评量表(SAS)、抑郁自评量表(SDS)筛选后无抑郁焦虑症状群的健康女性37例,2组年龄均介于40～60岁;主要评定工具为生活事件量表(LES)、艾森克人格问卷(EPQ)、应付方式问卷、汉密尔顿抑郁量表(HAMD)、SAS、SDS.结果 1.负性生活事件在女性围绝经期情绪障碍组(58.99±15.32)和健康对照组之间(17.28±8.03)存在着显著差异(P＜0.01);2.神经质(52.22±10.07vs 33.23±4.92)、精神质(57.39±1.26 vs 47.45±14.56)、内外倾性(45.77±12.79 vs 36.33±1.19)在女性围绝经期情绪障碍组和健康对照组之间存在着显著差异(P＜0.001);3.自责的应付方式在女性围绝经期情绪障碍组(0.53±0.28)和健康对照组之间(0.17±0.20)存在着显著差异(P＜0.001);结论生活事件、人格特征、应付方式等社会心理因素影响着女性围绝经期情绪障碍的发生、发展.展开更多
目的总结并分析围绝经期女性腰椎1-4、股骨颈及髋关节部位的骨密度(bone mineral density,BMD)及其临床特点。方法收集2017年12月至2018年6月在我院住院部住院并进行双能X线吸收法骨密度检测的183例围绝经期女性,分别测定其腰椎1-4总体...目的总结并分析围绝经期女性腰椎1-4、股骨颈及髋关节部位的骨密度(bone mineral density,BMD)及其临床特点。方法收集2017年12月至2018年6月在我院住院部住院并进行双能X线吸收法骨密度检测的183例围绝经期女性,分别测定其腰椎1-4总体BMD、左侧股骨颈及左髋关节全部BMD,同时分析比较年龄、体质量指数(body mass index,BMI)与骨质疏松的关系。结果 183例患者中,检出骨质疏松39例(21.3%),其中腰椎1-4、左股骨颈和左髋关节BMD各检出骨质疏松33例(18.0%)、20例(10.9%)、13例(7.1%)。腰椎总体骨质情况与股骨颈、髋关节检查结果相符的各有129例(70.5%)、119例(65.0%),股骨颈总体骨质情况与髋关节检查结果相符的有137例(74.9%)。在骨质疏松组、骨量减少组和骨量正常组,同一组病人腰椎1-4骨密度>左髋关节骨密度>左侧股骨颈骨密度,组间差异均有统计学意义。年龄、BMI与骨质疏松的发生均相关。骨质疏松与年龄呈正相关,与BMI、腰椎1-4总BMD、左股骨颈BMD、左髋关节BMD负相关,腰椎1-4 BMD与骨质疏松相关程度最高。结论腰椎整体骨密度呈现虚假升高趋势,腰椎1-4 BMD诊断骨质疏松的敏感性和特异性分别为84.6%、100%,股骨颈分别为51.3%、100%,髋关节分别为33.3%、100%;年龄增长、BMI偏低会增加围绝经期妇女罹患骨质疏松的风险。展开更多
文摘OBJECTIVE: To assess the effectiveness and safety of Kuntai capsule and hormone replacement therapy in treatment of perimenopausal syndrome.METHODS: Articles were retrieved from the databases Cochrane Database of Systematic Reviews,Pub Med, Chinese National Knowledge Infrastructure, China Science and Technology Journal Database, and Wanfang Database. Only randomized controlled trials were included; 15 trials involving1243 patients were identified from January 2005 to April 2015. A systemic review and Meta-analysis of publications was performed. The review was limit-ed to randomized controlled trials that compared Kuntai capsule and hormone replacement therapy to treat perimenopausal syndrome for at least 3months. The primary outcome assessed was the treatment efficacy at 3 months, including effective rate of Kupperman menopausal scores, Kupperman menopausal scores, and blood estradiol(E2) or blood follicle stimulating hormone(FSH) levels.Other outcomes assessed were safety or adverse events, such as gastrointestinal complaints, breast distending pain, or vaginal bleeding.RESULTS: Kupperman menopausal scores showed no significant difference in effective rate [odds ratio(OR): 1.05, 95% confidence intervals(CI): 0.71 to1.55] and changes in FSH level [mean difference(MD): 2.14, 95% CI:-2.36 to 6.65]. There was a significant statistical difference in Kupperman menopausal scores(MD:-1.14, 95% CI:-2.03 to-0.25)and changes in E2level(MD:-16.41, 95% CI:-18.83to-13.69). There were fewer adverse events in the Kuntai capsule group than in the hormone replacement therapy group(OR: = 0.35, 95% CI: 0.25 to0.48, P < 0.01).CONCLUSION: Compared with hormone replacement therapy, Kuntai capsule can improve perimenopausal symptoms and blood E2 levels, and reduce the incidence of adverse events.
文摘目的通过对女性围绝经健康人群和情绪障碍人群的临床对比研究,以期探索生活事件、人格特征、应付方式等社会心理因素在女性围绝经期情绪障碍中的作用.方法研究对象为在中山大学附属第三医院心理科住院的抑郁为主伴或不伴焦虑的围绝经期女性患者57例,以及来自到广州市海珠区妇幼保健医院参加体检的、经焦虑自评量表(SAS)、抑郁自评量表(SDS)筛选后无抑郁焦虑症状群的健康女性37例,2组年龄均介于40～60岁;主要评定工具为生活事件量表(LES)、艾森克人格问卷(EPQ)、应付方式问卷、汉密尔顿抑郁量表(HAMD)、SAS、SDS.结果 1.负性生活事件在女性围绝经期情绪障碍组(58.99±15.32)和健康对照组之间(17.28±8.03)存在着显著差异(P＜0.01);2.神经质(52.22±10.07vs 33.23±4.92)、精神质(57.39±1.26 vs 47.45±14.56)、内外倾性(45.77±12.79 vs 36.33±1.19)在女性围绝经期情绪障碍组和健康对照组之间存在着显著差异(P＜0.001);3.自责的应付方式在女性围绝经期情绪障碍组(0.53±0.28)和健康对照组之间(0.17±0.20)存在着显著差异(P＜0.001);结论生活事件、人格特征、应付方式等社会心理因素影响着女性围绝经期情绪障碍的发生、发展.
文摘目的总结并分析围绝经期女性腰椎1-4、股骨颈及髋关节部位的骨密度(bone mineral density,BMD)及其临床特点。方法收集2017年12月至2018年6月在我院住院部住院并进行双能X线吸收法骨密度检测的183例围绝经期女性,分别测定其腰椎1-4总体BMD、左侧股骨颈及左髋关节全部BMD,同时分析比较年龄、体质量指数(body mass index,BMI)与骨质疏松的关系。结果 183例患者中,检出骨质疏松39例(21.3%),其中腰椎1-4、左股骨颈和左髋关节BMD各检出骨质疏松33例(18.0%)、20例(10.9%)、13例(7.1%)。腰椎总体骨质情况与股骨颈、髋关节检查结果相符的各有129例(70.5%)、119例(65.0%),股骨颈总体骨质情况与髋关节检查结果相符的有137例(74.9%)。在骨质疏松组、骨量减少组和骨量正常组,同一组病人腰椎1-4骨密度>左髋关节骨密度>左侧股骨颈骨密度,组间差异均有统计学意义。年龄、BMI与骨质疏松的发生均相关。骨质疏松与年龄呈正相关,与BMI、腰椎1-4总BMD、左股骨颈BMD、左髋关节BMD负相关,腰椎1-4 BMD与骨质疏松相关程度最高。结论腰椎整体骨密度呈现虚假升高趋势,腰椎1-4 BMD诊断骨质疏松的敏感性和特异性分别为84.6%、100%,股骨颈分别为51.3%、100%,髋关节分别为33.3%、100%;年龄增长、BMI偏低会增加围绝经期妇女罹患骨质疏松的风险。
